Shell Asset Management CO Global Blood Therapeutics, Inc. Transaction History

Shell Asset Management CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$32.4 - $68.18 $17,982 - $37,839	-555 Reduced 20.04%	2,214 $151,000
Q2 2022 Aug 09, 2022	BUY	$22.3 - $37.39 $223 - $373	10 Added 0.36%	2,769 $88,000
Q1 2022 May 04, 2022	SELL	$25.68 - $35.59 $10,682 - $14,805	-416 Reduced 13.1%	2,759 $96,000
Q4 2021 Feb 09, 2022	SELL	$24.9 - $40.26 $1,294 - $2,093	-52 Reduced 1.61%	3,175 $93,000
Q3 2021 Nov 04, 2021	SELL	$25.48 - $37.34 $3,312 - $4,854	-130 Reduced 3.87%	3,227 $82,000
Q1 2021 May 10, 2021	SELL	$38.94 - $50.85 $36,759 - $48,002	-944 Reduced 21.95%	3,357 $137,000
Q2 2020 Aug 10, 2020	SELL	$48.73 - $81.82 $4,142 - $6,954	-85 Reduced 1.94%	4,301 $272,000
Q1 2020 May 11, 2020	SELL	$41.72 - $87.2 $2,795 - $5,842	-67 Reduced 1.5%	4,386 $224,000
Q4 2019 Feb 13, 2020	SELL	$45.7 - $81.86 $6,032 - $10,805	-132 Reduced 2.88%	4,453 $354,000
Q3 2019 Nov 12, 2019	SELL	$45.35 - $57.91 $1,768 - $2,258	-39 Reduced 0.84%	4,585 $222,000
Q2 2019 Aug 12, 2019	SELL	$52.6 - $63.29 $5,575 - $6,708	-106 Reduced 2.24%	4,624 $243,000
Q1 2019 May 09, 2019	BUY	$39.99 - $53.48 $189,152 - $252,960	4,730 New	4,730 $250,000

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.